The Billion-Dollar Gamble: AI Slashes Trial Costs as CF Drug Collapse Wipes 92% Off Sionna

AI-powered clinical monitoring agents are delivering up to $21 million in net financial value per drug development program, according to a new Tufts Center for the Study of Drug Development analysis. The technology, tested by Medable in oncology trials, shaved approximately 10 weeks off late-stage cancer drug development and reduced direct operating costs by as much as $5.6 million per phase 3 study. The efficiencies scale with a drug's potential uses: a...